Posted by Michael Wonder on 02 Feb 2017
Teva confirms generic Victoza patent challenge in the United States
2 February 2017 - Teva Pharmaceuticals today announced that it has filed an abbreviated new drug application with the U.S. FDA seeking approval to market the generic version of Novo Nordisk's Victoza (liraglutide) injection, in the U.S. Victoza is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Based on available information, Teva believes it is a "first applicant" to file an application for the generic version of Victoza; should its application be approved, Teva may be entitled to 180 days of generic market exclusivity.
